Click to Download
PRESS RELEASE
18 June 2025
Press Release
IB Communications
Advanced Therapies Think Tank Launches with Powerhouse Faculty Ahead of First Episode on CGT in Community Healthcare
LONDON, UK & WYOMING, US, June 18, 2025 — Advanced Therapies Think Tank (AT3) has unveiled its Season One Faculty ahead of the inaugural episode launching on July 3. With legendary names like Carl June alongside rising voices like Nicole Paulk and Anji Miller, this think tank has been designed to combine serious weight and fresh perspective to some of the sector’s thorniest challenges.
AT3 is a new, independent platform created by Lee Buckler, Sven Kili and Michelle Boxall. Its mission: to provoke smarter, faster critical thinking in cell and gene therapy (CGT) by those deeply entrenched in the space through structured, unscripted discussion. Following a successful pilot at Advanced Therapies Week in Dallas, AT3 kicks off its first season with six episodes tackling some of the major challenges in CGT - from access models and data dilemmas to the future of autologous therapy.
“We realized some of the most useful industry insights at conferences don’t come from the presentations or podcasts, they happen in ‘side’ conversations and fireside chats,” said co-founder Lee Buckler. “Leaving press releases and corporate titles at the front door, we’re bringing those moments online, making them regular, punchy, and game-changing by design.
Faculty for Season One includes: Anthony Davies, Farzin Farzaneh, Miguel Forte, Nina Horowitz, Carol Houts, Carl June, Anji Miller, Luigi Naldini, Raphael Ognar, Nicole Paulk, Angela Vollstedt, and Claudia Zylberberg, alongside hosts Lee Buckler, Sven Kili and Audrey Greenberg.
“We’ve curated a faculty that reflects where this industry has been, and where it’s going,” said co-founder Michelle Boxall. “Their willingness to ask uncomfortable questions and passion to think outside of the box to find solutions is exactly what this platform was built for.”
Season One Line-Up
August 7 – The CGT pricing dilemma
September 11 – Could different business models enable better access to CGTs?
October 2 – How do we disrupt the pharma innovation model to do things faster, cheaper, better?
November 6 – Wouldn’t a pre-competitive model help us break through common challenges much faster and cheaper for the benefit of all?
December 4 – Will autologous ex vivo cell therapy always exist, or is it just a blip on our way to in vivo or other biological therapies?
Co-founder Sven Kili adds, “AT3 isn’t a classroom. It’s an unfiltered, un-scripted think tank for those ready to shape the future, not just understand the challenges of the present. It’s not about education but exploration, with every session assuming a high bar of expertise so we can dive straight into what matters: bold assertions, hard questions, and actionable ideas that move the field forward.”
Beyond the episodes, AT3’s function as an active think tank will also include developing insights drawn from the discussions into targeted industry reports and White Papers, offering strategic value that continues to shape thinking long after the debate ends. AT3 is currently inviting sponsors who want to align their brand with a bold, solutions-driven initiative that’s redefining how the sector tackles its biggest challenges.
More at: www.advancedtherapiesthinktank.com